RBC Bioscience Corporation (TPEX:6848)
Taiwan · Delayed Price · Currency is TWD 20.60
+0.90 (4.57%)
Jun 12, 2026, 1:50 PM CST
RBC Bioscience Revenue
In the year 2025, RBC Bioscience had annual revenue of 219.71M TWD with 7.05% growth. RBC Bioscience had revenue of 112.01M in the half year ending December 31, 2025, with 34.10% growth.
Revenue
219.71M
Revenue Growth
+7.05%
P/S Ratio
1.35
Revenue / Employee
4.39M
Employees
50
Market Cap
297.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 219.71M | 14.46M | 7.05% |
| Dec 31, 2024 | 205.25M | 32.78M | 19.01% |
| Dec 31, 2023 | 172.47M | -1.42M | -0.82% |
| Dec 31, 2022 | 173.89M | -77.29M | -30.77% |
| Dec 31, 2021 | 251.18M | -323.98M | -56.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLASCO Taiwan | 263.81M |
| Visgeneer | 179.06M |
| Feng Chi Biotech | 177.36M |
| NatureWise Biotech & Medicals | 176.77M |
| Vectorite Biomedical | 61.41M |
| Neith | 32.03M |
| SynCore Biotechnology Co.,Ltd | 27.78M |
| Eusol Biotech | 2.08M |